Navigation Links
Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
Date:1/4/2011

ROCHESTER, N.Y., Jan. 4, 2011 /PRNewswire/ -- Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors.

(Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO)

VX15/2503 is a novel humanized antibody that blocks the activity of semaphorin 4D (SEMA4D).  It is the first of two of the Company's therapeutic antibodies expected to begin clinical trials this year. "Advancing VX15 into the clinical stage of development is an exciting achievement for Vaccinex, and a testament to the experience and outstanding capabilities of our research and development teams," said Ray Watkins, Senior Vice President and Chief Operating Officer of the company.

"SEMA4D is an exciting therapeutic target with remarkable biological properties relevant to several disease processes," said Dr. Maurice Zauderer, President and Chief Executive Officer of Vaccinex.  As reflected in its name, semaphorin, the molecule guides the activation and movement of different cell types in different ways.  For example, SEMA4D promotes migration of tumor cells that metastasize to new locations as well as the outgrowth of cells that form new blood vessels required to provide nutrients and energy to tumors.  It is anticipated that, by blocking this signal, the anti-SEMA4D antibody will both inhibit the growth of primary tumors and limit metastases to new sites.  "This is important," Dr. Zauderer said, "because if tumors did not metastasize, then surgeons could cure cancer."  In other tissues and disease processes, for example damage to neurons in demyelinating diseases such as multiple sclerosis (MS), the same semaphorin has an opposite effect on outgrowth of cells, preventing the regeneration and remyelination of damaged neurons.  In this case, Dr. Zauderer said, "The VX15/2503 antibody has the potential to be a radical new approach to treatment of MS, acting both as an anti-inflammatory to protect against disease progression but also promoting healing of damaged tissue."  Vaccinex plans to initiate a second trial of VX15/2503 for MS later this year.  

About Vaccinex, Inc.

Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs.   http://www.vaccinex.com/.

Press Contact

Raymond E. Watkins, Chief Operating Officer, 585.271.2700 (x-105)

e-mail: rwatkins@vaccinex.com


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
2. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
3. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
4. GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
5. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
6. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
7. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
8. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
9. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
10. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
11. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):